Beam Therapeutics Inc. short interest in 2026
In 2026, Beam Therapeutics Inc.'s disclosed short interest ran from 19.75% of shares outstanding on 15 Jan 2026 to 25.06% on 15 Sep 2026, a change of +5.31 percentage points. The year's high was 27.52% on 15 Jun 2026 and its low 19.13% on 30 Jan 2026, averaging 22.47% across 17 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 16.08 days on 14 Aug 2026. Full history: Beam Therapeutics Inc..
Cite this page
By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2026 in figures
- Start of year
- 19.75% (15 Jan 2026)
- End of year
- 25.06% (15 Sep 2026)
- Change
- +5.31 pp
- High
- 27.52% (15 Jun 2026)
- Low
- 19.13% (30 Jan 2026)
- Average
- 22.47%
- Highest days to cover
- 16.08 (14 Aug 2026)
- SEC filings marked
- 7
Every report in 2026
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2026 | 19.75% | 8.55 | results (8-K) |
| 30 Jan 2026 | 19.13% | 10.11 | |
| 13 Feb 2026 | 19.93% | 13.49 | |
| 27 Feb 2026 | 21.57% | 13.62 | 10-K filed, results (8-K) |
| 13 Mar 2026 | 20.99% | 10.61 | |
| 31 Mar 2026 | 23.02% | 10.65 | |
| 15 Apr 2026 | 21.90% | 11.05 | |
| 30 Apr 2026 | 20.35% | 9.51 | |
| 15 May 2026 | 25.77% | 12.57 | 10-Q filed, results (8-K) |
| 29 May 2026 | 20.86% | 11.73 | |
| 15 Jun 2026 | 27.52% | 14.22 | |
| 30 Jun 2026 | 22.24% | 8.38 | |
| 15 Jul 2026 | 22.57% | 8.93 | |
| 31 Jul 2026 | 22.75% | 11.31 | |
| 14 Aug 2026 | 23.60% | 16.08 | 10-Q filed, results (8-K) |
| 31 Aug 2026 | 24.98% | 14.84 | |
| 15 Sep 2026 | 25.06% | 12.59 |
See also: Beam Therapeutics Inc.'s full history · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.